Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients

Inclusion Criteria: * Male or female patients having ≥18 years of age * Women of child bearing capacity who are not pregnant at the moment of screening (Pregnancy test done on-site) and agree to use an acceptable form of birth control for the duration of the study (e.g. condom, oral contraceptives, etc.) are allowed to participate. * Patients must have nasal MRSA colonization confirmed with MRSA positive culture as assessed during the screening visit without any clinical signs or symptoms of infection. * Laboratory test results within the normal ranges. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patients treated for nasal MRSA decolonization in the last 6 months; * Current infection with MRSA; * Ongoing or active infection; * Daily probiotic/ fermented milk or Yogurt use; * Known to have shown a previous reaction, including anaphylaxis, to any substance in composition of the study agent (capsules); * Ongoing or recent use of antibiotics in the 30 days prior to the study agent administration; * Pregnancy, breastfeeding; * Regular use of nasal agents; * Uncontrolled intercurrent illness, including situations that would limit compliance with study requirements; * Patients with open wounds * Immunosuppressive therapy or any health condition causing inmunosuppression (Including Haematological malignancies, AIDS); * Ostomized patients, parenteral nutrition users; * Patients with current vascular access (catheter…